Skip to main content

Jessica Hagen

By Jessica Hagen | 05:34 pm | December 04, 2023
The company's CEO said it is leaving the CMS program at the end of the performance year due to not seeing a clear path to profitability.
By Jessica Hagen | 02:04 pm | December 04, 2023
The gastrointestinal surgery-focused company will use the funds to advance its endoluminal robotics technology for minimally invasive procedures.
By Jessica Hagen | 06:16 pm | December 01, 2023
Rx Savings Finder allows Walgreens' pharmacy customers to access low-cost prescriptions by comparing the price of medications on third-party discount cards.
By Jessica Hagen | 01:33 pm | November 30, 2023
The company scored Class III Shonin clearance in Japan for its stroke platform and launched Rapid Edge Cloud, allowing continued AI access despite cloud connectivity.
By Jessica Hagen | 01:40 pm | November 29, 2023
The partnership will give St. Luke's Health System employees access to TytoCare's Home Smart Clinic and its plan members access to virtual visits with a $0 copay.
By Jessica Hagen | 06:10 pm | November 28, 2023
The funds will be used to develop a comprehensive AI imaging model powered by imaging data to improve diagnostic precisions and early detection of conditions.
By Jessica Hagen | 03:22 pm | November 28, 2023
The low-cost drug service will be part of Florida-based PharmcoRx's in-pharmacy offerings and will integrate into Expion Health's product suite.
By Jessica Hagen | 01:07 pm | November 28, 2023
The company showcased new informatics solutions at RSNA23 in Chicago, including a "helium-free" mobile MRI system and an AI-enabled advanced visualization workshop.
By Jessica Hagen | 02:21 pm | November 27, 2023
A study published in the New England Journal of Medicine says GPT-4 correctly diagnosed 52.7% of complex cases compared to only 36% of medical journal readers.
By Jessica Hagen | 05:12 pm | November 22, 2023
The company's product, Distill, uses machine learning algorithms and LLMs to perform administrative, clinical and research tasks that require chart review.